CliffBio
biologic

Prolia

denosumab

Loss of exclusivity—loss of exclusivity
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameProlia
Active ingredientdenosumab
Strength60MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.